Literature DB >> 17122506

The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN).

Monica Srodon1, Mark H Stoler, Gwen B Baber, Robert J Kurman.   

Abstract

It has been proposed that low-grade vulvar and vaginal lesions (VIN 1 and VaIN 1) are flat condylomas and should be designated as such. Moreover, their relationship to high-grade lesions (VIN 3 and VaIN 3) is unclear. Accordingly, this study was undertaken to address these issues by comparing the distribution of human papillomavirus (HPV) types in vulvar and vaginal intraepithelial lesions. We identified 33 cases of VIN 1, 34 cases of VIN 3, 17 cases of VaIN 1, and 16 cases of VaIN 3. In addition, 36 cases of low-grade squamous intraepithelial lesion (LSIL) in the cervix and 116 cases of cervical high-grade squamous intraepithelial lesion were used for comparison. Polymerase chain reaction analysis was performed using both the Roche PGMY and DDL SPF 10 systems. In cases where HPV was detected, the majority of low-grade and high-grade lesions contained a single HPV type. However, a minority of cases were found to have multiple HPV types. Of the VIN 1 cases, a low-risk virus was seen in 22 (67%), with HPV 6 or 11 accounting for 14 (42%). A high-risk virus was detected in 14 (42%) of cases of which 2 (6%) contained HPV 16. Of the VIN 3 cases, all had high-risk HPV of which 31 (91%) were found to have HPV 16. Of the VaIN 1 cases, 6 (35%) were found to have low-risk HPV types. HPV 6 or 11 were not found in these cases. High-risk virus was seen in 13 (76%) VaIN 1 cases, with 1 (6%) containing HPV 16. HPV was detected in 15 of 16 (94%) VaIN 3 lesions, all of which had high-risk types. HPV 16 was found in 8 (50%). In contrast, 2 (6%) of cervical LSIL had low-risk HPV (HPV 6 and 11), whereas 34 (94%) of LSIL cases had high-risk HPVs. Of the cervical high-grade squamous intraepithelial lesion cases, 100% had high-risk HPVs of which 87 (75%) were found to have HPV 16. The findings demonstrate that a significant number of low-grade vulvar and vaginal lesions contain high-risk HPV types, supporting their designation as low-grade intraepithelial lesions rather than flat condylomas. The low frequency of HPV 16 in VIN 1 compared with VIN 3 suggests they are distinct lesions or that HPV 16 is critical in the progression to VIN 3. Finally, comparison of the distribution of HPV in the vagina and vulva suggests that VaIN is more closely related to cervical intraepithelial neoplasia than to VIN.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17122506     DOI: 10.1097/01.pas.0000213291.96401.48

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  30 in total

Review 1.  Human papillomavirus infections in primary care.

Authors:  Folashade Ogunmodede; Steven H Yale; Bruce Krawisz; Gregory C Tyler; Anthony C Evans
Journal:  Clin Med Res       Date:  2007-12-17

Review 2.  A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results.

Authors:  Michelle J Khan; L Stewart Massad; Walter Kinney; Michael A Gold; E J Mayeaux; Teresa M Darragh; Philip E Castle; David Chelmow; Herschel W Lawson; Warner K Huh
Journal:  Gynecol Oncol       Date:  2016-02-22       Impact factor: 5.482

Review 3.  [Nomenclature of squamous cell precursor lesions of the lower female genital tract : Current aspects].

Authors:  L-C Horn; C E Brambs; R Handzel; G Mehlhorn; D Schmidt; K Schierle
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

4.  Comparison of the INNO-LiPA and PapType assays for detection of human papillomavirus in archival vulva dysplasia and/or neoplasia tissue biopsy specimens.

Authors:  Sarah E Tan; Suzanne M Garland; Alice R Rumbold; Sepehr N Tabrizi
Journal:  J Clin Microbiol       Date:  2011-09-21       Impact factor: 5.948

Review 5.  [HPV-associated alterations of the vulva and vagina. Morphology and molecular pathology].

Authors:  L-C Horn; K Klostermann; S Hautmann; A K Höhn; M W Beckmann; G Mehlhorn
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

6.  Coexisting high-grade vulvar intraepithelial neoplasia (VIN) and condyloma acuminatum: independent lesions due to different HPV types occurring in immunocompromised patients.

Authors:  Kruti P Maniar; Brigitte M Ronnett; Russell Vang; Anna Yemelyanova
Journal:  Am J Surg Pathol       Date:  2013-01       Impact factor: 6.394

7.  Human papillomavirus-related gynecologic neoplasms: screening and prevention.

Authors:  Whitfield B Growdon; Marcela Del Carmen
Journal:  Rev Obstet Gynecol       Date:  2008

8.  Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

Authors:  Joakim Dillner; Susanne K Kjaer; Cosette M Wheeler; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; F Xavier Bosch; Elmar A Joura; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Roger Maansson; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Eliav Barr; Richard Haupt
Journal:  BMJ       Date:  2010-07-20

Review 9.  A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States.

Authors:  Ralph P Insinga; Kai-Li Liaw; Lisa G Johnson; Margaret M Madeleine
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07       Impact factor: 4.254

10.  Nucleotide variation in IL-10 and IL-12 and their receptors and cervical and vulvar cancer risk: a hybrid case-parent triad and case-control study.

Authors:  Shehnaz K Hussain; Margaret M Madeleine; Lisa G Johnson; Qin Du; Denise A Galloway; Janet R Daling; Mari Malkki; Effie W Petersdorf; Stephen M Schwartz
Journal:  Int J Cancer       Date:  2013-02-12       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.